BiotechTube

FCH

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Congenital Fibrinogen Deficiency

Conditions

Congenital Fibrinogen Deficiency

Trial Timeline

May 7, 2015 → Dec 6, 2017

NCT ID
NCT02427217

About FCH

FCH is a pre-clinical stage product being developed by CSL for Congenital Fibrinogen Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT02427217. Target conditions include Congenital Fibrinogen Deficiency.

What happened to similar drugs?

4 of 20 similar drugs in Congenital Fibrinogen Deficiency were approved

Approved (4) Terminated (0) Active (16)
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄turoctocog alfa pegolNovo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄vatreptacog alfa (activated) + eptacog alfa (activated)Novo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
✅turoctocog alfaNovo NordiskApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02427217Pre-clinicalCompleted

Competing Products

20 competing products in Congenital Fibrinogen Deficiency

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29